August 11, 2026: What if diabetic foot complications could be detected earlier, without patients having to reach a tertiary hospital? Bengaluru-based medical technology startup Ayati Devices is building its business around that question.
The company has raised Rs 15 crore ($1.5 million) in a Pre-Series A funding round led by Inflexor Ventures. The funding will support commercialisation, expansion across domestic and international markets, manufacturing capacity, and greater investment in research and artificial intelligence.
Founded in 2019 by Nishant Kathpal, Ayati Devices develops portable, point-of-care diagnostic technologies for diabetic foot complications and peripheral vascular disease. The startup was incubated at IIT Bombay’s Society for Innovation and Entrepreneurship (SINE).
Ayati Devices funding to help scale point-of-care diagnostics
Its portfolio is designed to address different aspects of diabetic foot assessment. Vibrasense measures vibration perception threshold to identify large-fibre peripheral neuropathy, while Vibrasense+T adds warm and cold perception testing. Vasosense focuses on peripheral artery disease screening, while Angiocam enables real-time tissue perfusion imaging.
The company has also introduced the PODIA Trolley, a pay-per-test screening model aimed at reducing the upfront investment required from healthcare providers.
Ayati Devices says its solutions have been deployed across 30 countries, with more than 10,000 devices deployed and over 1 million screenings enabled.
The company’s flagship Vibrasense has also undergone clinical evaluation. A study involving 562 people with type 2 diabetes compared Vibrasense-based vibration perception threshold testing with conventional biothesiometry and nerve conduction studies for screening diabetic peripheral neuropathy.
The funding comes as the healthcare industry continues to look beyond large hospitals for ways to make specialised diagnostics more accessible.
For Ayati, the next challenge is turning its technology footprint into a scalable healthcare business , taking screening closer to patients while building the manufacturing and commercial infrastructure needed to support that expansion.
That could make the company’s next phase as important as the funding itself.
